Consensus Omeros Corporation

Stocks

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
16.20 ^USD	-13.78%		-18.31%	-5.68%

10-16	Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency	MT
10-16	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Amid Investor Caution	MT

Evolution of the Average Target: Omeros Corporation

Evolution of the Target Price: Omeros Corporation

Changes in Analyst Recommendations: Omeros Corporation

f825815f9c560980968c03.tQZoak3SnzdykQWhFK-DzK_0D0MxGFkqIXlKESJ5X3s.4347KSW3_Vg2qWnFW-vWr8W_bSd4bBRzZSN8RHAoMDDbaDAtJJHQcAjaTA~88e7de0d7f7c70dd34a29e6df7270507

Analysts' recommendations: Omeros Corporation

09-22	Omeros Shares Rise After Cantor Fitzgerald Upgrade	MT
09-22	Cantor Fitzgerald Upgrades Omeros to Overweight From Neutral, Price Target is $22	MT
25-10-15	Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk	MT
25-06-10	HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target	MT
23-03-15	UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating	MT
22-12-08	UBS Downgrades Omeros to Neutral From Buy, Adjusts Price Target to $2 From $12	MT
22-11-09	BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3	MT
22-06-08	BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target	MT
22-01-18	Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating	MT
21-10-19	Omeros : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Rating	MT
21-10-15	Omeros : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, Maintains Buy Rating	MT
21-10-11	Omeros : Wedbush Suspended Coverage on Omeros	MT
21-10-08	Omeros : JPMorgan Downgrades Omeros to Underweight from Neutral	MT
21-10-06	Omeros : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating	MT
21-10-04	Omeros : Maxim Downgrades Omeros to Hold from Buy	MT
21-10-01	Omeros : Wedbush Downgrades Omeros to Underperform From Neutral, Lowers PT to $5 From $18 After FDA Delays PDUFA For Narsoplimab	MT
21-10-01	Omeros : Maxim Group Downgrades Omeros to Hold From Buy	MT
21-09-27	Omeros : JPMorgan Starts Omeros at Neutral With $15 Price Target	MT
21-06-18	Omeros : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target	MT
21-04-26	Omeros : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating	MT
21-02-01	Omeros : UBS Starts Omeros at Buy With $25 Price Target	MT
21-01-20	Omeros : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy Rating	MT
21-01-20	Omeros : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral Rating	MT
20-12-04	Omeros : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating	MT
20-11-17	Omeros : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OMEROS CORPORATION					+69.75%
	WUXI APPTEC CO., LTD.					+32.97%
	ARGENX SE					+38.45%
	LONZA GROUP AG					+14.74%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	BIONTECH SE					+33.01%
	Average					+32.70%
	Weighted average by Cap.					+28.34%